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Introduction 
In older  days communicable diseases threatens the people  invariably.  Most of 
the people died because of  unknown diseases which easily spreads to others. After the 
invention of penicillin the whole world came out from the communicable disasters. 
After the invention of many vaccines, a lot of communicable diseases are eliminated  
from the world. Because of modernization  and globalization the physical activity of 
the people is almost reduced. And because of  hybridization and adulteration patient 
food habits also changed drastically. Apart from this the environmental changes like 
air, water and land pollution makes the world  unfit for healthy survival. The scientific 
success of this era is changing of the world from communicable disease to non 
communicable disease.  
In this growing world many people are dying because of non communicable 
disease complications. In this century the most controllable and dreadful non 
communicable  disease is diabetes mellitus. Day by day the number of diabetic patient  
is increasing. As per new survey 425 million people are affected by diabetes 
throughout the world.  India’s diabetes population is 74 million on 2017. But it will 
touch 134.3 million by 2045.  Current expenditure of India is 31 billion dollars for 
diabetic health care management. 
Diabetes is not the simple term like elevated blood sugar level. It is the 
backbone of many  uncorrectable medical conditions. Every organ of our human body 
including  kidney, brain, heart, eyes are directly affected by diabetes and many organs 
are indirectly affected by diabetes in the term of poor healing, increased infection and 
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drug resistance. To prevent those complications keeping the diabetes in a controlled 
state is very important.  
Apart from the organs, diabetes  alters the metabolic components of the body. 
It produces the metabolic abnormality in both extreme like  hypocalcemia as well as 
hypercalcemia, hyponatremia and hypernatremia. Because of this metabolic  
abnormalities many internal structures which depends the metabolic products are also 
affected. Internal organelle dysfunction finally leads the organ dysfunction and death. 
Hypocalcemia is one of the important complication of diabetes mellitus. It 
occurs when the patient develops renal insufficiency. But hypercalcemia  occurs in 
diabetes due to many mechanisms including insulin resistance. Meanwhile 
hypercalcemia itself produces insulin resistance. And the calcium is the important one 
for the production of insulin and glucose uptake in the cells.  
Ionized serum calcium is the active form of calcium. Around 40% of calcium is 
protein bounded. Before commenting about the calcium level,  serum albumin should 
be considered. Because low serum albumin level have a effect on serum calcium. To 
avoid this things this study is conducted to evaluate the cardiac complication of  
calcium by excluding the conditions which produces hypoalbuminemia. By using the 
serum calcium (spot) we can able to identify the cardiac complications. 
Heart is the vital organ of our body. Any changes in the function of 
myocardium will affects the function of whole body system. Heart  is damaged by 
many conditions like hypertension, diabetes, dyslipedemia and also hypercalcemia. 
Eventhough the hypercalcemia is not defined as risk factor for cardiac  complication 
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in older days, many trials and studies are proved  that hypercalcemia will produce 
severe cardiac abnormality including systolic and diastolic dysfunction. 
In 1982 Hockman and Buckey  was coined the term “remodeling”. Remodeling 
is based on morphological changes of the heart. The morphological changes include 
ventricular cavity diameter, wall thickness,  scarred area. So the remodeling is defined 
as it is the morphological changes of the heart after injury. Myocardial ischemia is the 
important disease which produces ventricular remodeling and cardiac dysfunction.  
Apart from MI many cardiac conditions are benign and some are significant. But some 
benign condition will progresses into significant myocardial abnormality. cardiac 
muscle hypertrophy will occur in many subjects like athelets, pregnant women. But 
that  does not produce any significant damage. But a middle aged man or women 
develops the same hypertrophy  because of hypertension or diabetes or hypercalcemia 
which in turn leads to hypertrophic changes finally leading to cardiac failure, 
arrhythmias and death.  Cardiac hypertrophy will develops in many forms like 
concentric or eccentric. Hypertension and aortic stenosis produces concentric 
hypertrophy that is  called as pressure overload. Chronic mitral or regurgitation will 
produces eccentric hypertrophy that is known as volume overload. Hypercalcemia 
produces both pressure and volume overload.  This changes finally progresses into 
ventricular dysfunction and death. 
This hypertrophic changes can be easily detected by echocardiography. We can 
also predicts the left ventricular remodelling  by assessing serum calcium level in 
diabetic patients which can  be used to save the patient from cardiac failure. And 
many newer drugs are also identified to prevent the left ventricular remodeling.  
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Hypercalcemia can cause left ventricular remodeling by producing  vascular 
calcification and increases the calcineurin pathway. Apart from this way 
hypercalcemia also induces cardiac remodeling by altering the lipid metabolism. 
Hypercalcemia itself produces dyslipidemic effect by inhibiting the lipid catabolism in 
initial steps. Alteration  in the cytosolic calcium levels determines the ventricular 
systolic and diastolic dysfunction.  
Generally 8.5- 10.2 mg/dl is considered as  normal serum calcium as per 
standard text books. Symptoms of  hypercalcemia will develops if serum calcium 
increases more than 12. So the level 10.2 to 12 is the asymptomatic hypercalcemic 
level. This study is designed  to identify the association of  elevated serum calcium 
with  left ventricular remodeling in diabetic patients. 
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AIM OF THE STUDY 
 
 
Assess left ventricular dimension and wall thickness mass in diabetic  patients 
having high serum calcium level. 
OBJECTIVES:  
 Determination of  left ventricular dimension  in  diabetic patients  having 
high serum calcium 
 Effect of serum calcium on left ventricular remodeling through cholesterol 
profile alteration. 
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REVIEW OF LITERATURE 
Diabetes mellitus: 
Diabetes is called as Metabolic cum vascular disorder because it is due to 
altered metabolism of carbohydrate, protein, fats and these alteration will finally 
causes organ dysfunction. Organ dysfunction is due to Microvascular complication of 
diabetes. This Microvascular complication leads to permanent damage in kidney, 
heart, eyes and nerves. This effects in diabetes is due to either insulin deficiency or 
insulin resistance.  
Types of diabetes mellitus: 
Type 1 diabetes mellitus – beta cell destruction diabetes: 
Insulin dependant diabetes mellitus term is now obsolete. Rather than that term 
now it is called insulin deficient diabetes mellitus. Major mechanism of this type is 
pancreatic beta cell destruction. This destruction is due to either autoimmune cause or 
idiopathic cause.  Main auto antibodies are islet cell antibodies and glutamic acid 
decarboxylase (GAD) antibodies. In idiopathic variety  there wil be no auto antibodies 
but this variety is associated with other auto immune disorders like autoimmune 
addisons, auto immune thyroiditis, ovarian failure, vitiligo and poly glandular 
autoimmune disorder. This type 1 diabetes will occurs mainly children and 
adolescents. The slow onset type of type 1 DM is also called as late onset autoimmune 
diabetes of adults (LADA).  Hyperglycemia, coma, ketosis  due to sudden withdrawal 
of insulin is more common in type 1 diabetes mellitus. 
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Type 2 diabetes mellitus – resistant or secretory defect diabetes: 
Mechanism of type 2 diabetes is receptor or post receptor level insulin 
resistance. And it is also due to increased hepatic glucose production. s. In type 2 
diabetes insulin and C peptide level will be normal to high. compared with type 1, 
coma, ketosis are rare in type 2 diabetes mellitus.  
MODY : 
Early onset of type 2 diabetes mellitus is called MODY (maturity onset 
diabetes of the young). It will occur before 25 years of age. In MODY there is strong 
family history upto three or more generations.   But the MODY patients does not have 
any auto antibodies. It is autosomal dominant pattern there are 6 types of MODY is 
present. 
MODY type 1- hepatocyte nuclear factor 4 alpha (HNF 4 α)  
MODY type 2 – Glucokinase defect 
MODY type  3- hepatocyte nuclear factor  1 alpha (HNF 1 α) 
MODY type 4-  insulin promoter factor-1 (IPF-1) 
MODY type 5- hepatocyte nuclear factor  1 beta  (HNF 1 β) 
MODY type 6- nuclear differentiation factor 
Gestational diabetes mellitus: 
This is special variety of glucose intolerance developed during pregnancy. 
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Other than these some endocrine disease like cushing syndrome, auto immune 
addisons and hypothyroidism also causes hyperglycemia. Drugs like glucocorticoides, 
ACTH,  thiazides, pentamidine and phenytoin also causes hyperglycemia. Sometimes 
malnutrition related diabetes mellitus will also occurs due to fibro calculous pancreas 
and protein deficiency. The main clinical features of fibro calculous pancreopathy is 
hyperglycemia, abdominal pain which occurs repeatedly and pancreatic calculus. 
About 2-4 % patients of down syndrome and turner syndrome will develops diabetes. 
Mechanism of endogenous insulin secretion and role of calcium: 
 
 
 
 
 
 
Carbohydrates, proteins, fat, hormonal factors and neural factors all plays a key 
role  in insulin release. Glucose is the major determinant of insulin release. GLUT 4 
receptors transports the glucose into the beta cells of pancreas. Glucose dependant 
insulin release is usually biphasic manner.(1) Acute insulin release is the first phase 
which lasts for initial 5-10 minutes. Second phase of prolonged phase persists till high 
glucose levels become decreased. If glucose level is less than 90 mg/dl that will affect 
the insulin release. In resting state ATP modulated potassium channels will kept open 
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and voltage gated calcium channels is closed. When glucose enters into beta cell it 
causes depolarization of the cell membrane that closes potassium channels and opens 
voltage gated calcium channels. This leads to calcium influx into the cells and releases 
insulin. This process called exocytosis. 
Apart from glucose other enzymes like glucagon and somatostatin release 
insulin by paracrine action. this gut hormones increases the insulin release following 
meal instead of parentral administration. This effect is called incretin effect. 
Hypothalamo-enter-insulin axis by vagal nerve also stimulates insulin release which 
effect is called neural effect. In type 2 diabetes mellitus insulin resistance is due to two 
effects. 1.normal response will occurs after supra normal levels of insulin 2. Massive 
doses of insulin also not able to bring the sugar values into normal. Those effects are 
called decreased sensitivity and decreased responsiveness respectively. 
Diabetes and cardiac complication: 
         Uncontrolled diabetes produces adverse effects on cardiovascular system like 
coronary artery disease, cardio myopathy, cardiac failure and cardiac autonomic 
neuropathy. 
Cardiomyopathy:  
 In diabetic patients function alteration of myocardium and cavity dilatation 
will occur. Diffuse ischemia is the major mechanism for diabetic cardiomyopathy. In 
diabetic cardiomyopathy atherosclerotic changes will occurs in intramural arteries but 
in myocardial infarction cases the  atherosclerotic occlusion will occurs in extramural 
vessels.  Histologically increased accumulation connective tissue in the myocardium  
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which the intramural small vessels. The saccular aneurysms will occurs in 
myocardium in a localized manner. In diabetes morphological analysis shows 
increased glycoprotein material in myocardium with less compliant ventricular wall. 
Addition to that increased production of type 1 pro collagen by tunica media will also 
be  responsible  for diabetic cardiomyopathy. In diabetes reduced calcium uptake and 
decreased  will  also be responsible for cardiomyopathy. 
Glucose works as fuel for myocardial contraction also. In diabetes ineffective 
or insufficient action on insulin leads to increased formation of extra cellular sorbitol 
and fructose. These osmotically active substances prevents oxygen supply to 
myocardium that leads to cardiomyopathy. In initial stages of diabetic 
cardiomyopathy only non specific ST T changes will occurs. Later stages 
echocardiography examination shows increased wall thickness. The increased ratio of 
pre ejection period/left ventricular ejection time attributes to in coordinated 
myocardial contraction.  Abnormalities of left ventricular relaxation also occurs in 
diabetes patients.  The peak rate of LV filling and wall thickening by M mode echo is 
also gives about clue of diabetic cardiomyopathy.  Evaluation of diastolic dysfunction 
is strong predictor of cardiovascular disease in diabetic patients. Coronary 
atherosclerosis due to diabetes leads to myocardial scarring, fibrosis and reduced 
ventricular distensibility.  The thickness of ventricular septum correlates with ambient 
insulin concentration. In diabetes high incidence of heart failure and mortality is 
explained by an underlying diabetic cardiomypathy. This will be exaggerated by 
systemic hypertension and previous ischemic heart diseases. Autonomic damage to 
the myocardium is responsible for painless myocardial infarction.  In diabetes  cardiac 
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autonomic neuropathy parasympathetic function shows abnormalities earlier 
compared to sympathetic system.                 
Calcium: 
Calcium is an important mineral element of our body.  1.5-2 per cent of the 
bodyweight of an adult human is made up of calcium mineral. Normally an  average 
adult human body contains around 1200g of calcium. Of these 98% of calcium is  
found in the bones. Around 30 g of calcium is required for developing fetus. In human 
body calcium is available in many forms. 40 % are plasma protein bound that are not 
filterable by kidney. 60 % are ultra filterable form that are excreted by kidney. In that 
ultra filterable form 10% are bound with phosphates, carbonates and sulphates. 50 % 
are in free form. This free form calcium called as ionized calcium. This ionized 
calcium is metabolically active form. 
Functions: 
Plasma ionized calcium modulates  many vital  functions including formation 
of bones and teeth, cardiac function, contraction of skeletal  muscles, coagulation of 
blood and, milk production. And it also important for the transmission  of electrical 
and chemical messages that arrive at a cell membrane and keeps   the cell membrane 
intact. Calcium is useful for the metabolism of enzymes  and  many hormones. In the 
retina, it  transforms  the  light energy to electrical impulse. As a whole, calcium ion 
controls many vital functions  ranging from muscle contraction to cell division and 
cell death. 
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Absorption: 
Milk, egg, fish are high calcium rich and readily available calcium sources. The 
green leafy vegetables, cereals and millets are  cheapest dietary sources of calcium. 
calcium is highly present in ragi. Rice is a poor source of calcium. Normally about 20-
30 percent of dietary calcium is absorbed in human body. Absorption of calcium is 
decresed by the presence of phytates, oxalates, and fatty acids in the diet and 
absorption enhaced by vitamin D.  
 
 
 
 
 
 
Calcium homeostasis: 
Three organs of our body maintain calcium homeostasis are bone, GI system 
and kidney. Calcium is absorbed in GI tract. 99 % calcium deposited in bones along 
with phosphates. Fine tuning of handling of calcium is modulated by nephrons.  In 
healthy states excessive calcium is eliminated by kidney. And in deficient states 
kidneys reabsorbs calcium. Three hormones regulates calcium homeostasis.  
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1. parathormone  from chief cells of  parathyroid gland  
2. active form of vitamin D secreted by proximal tubular convoluted tubules 
3. calcitonin from para follicular cells of thyroid gland.   
Parathormone:  
Diminished free calcium is the important stimulator of parathormone. Calcium 
receptors are present in the surface of the chief cells. These receptors are G protein 
coupled receptor. In acute calcium deficient states the ionized calcium stimulates the 
granules in which parathormone are stored. In chronic calcium deficient state the 
ionized calcium not only stimulates the granules but also nucleus which tends to 
produce more parathormone. Parathormone released in a state of pre pro 
parathormone. Then it cleaves and forms parathormone. 
There are two types osteal cells. Osteoblasts and osteoclasts. Osteoblasts 
produces bone mineralization and osteoclasts causes demineralization. In body type 1 
collagen is present in bone. It gives tensile strength to the bone. 
If serum calcium level is reduced in systemic circulation it activates 
parathormone hormone. Parathormone receptor present in osteoblasts not in 
osteoclasts. Parathormone enters in osteoblast cells by G protein coupled receptor and 
produces more amount of adenyl cyclase and cyclic AMP. This cyclic AMP produces 
protein kinase A which activates the nucleus of osteoblasts and produces some 
proteins. those proteins are attaches into osteoclasts and activates it.  In bone calcium 
is bound with phosphate makes hydroxyappetite complex which gives strength to 
bone. This calcium, phosphate, collagen forms bone mineralization. Osteoclasts 
17 
 
attaches to the collagen with integrins. After that it will secretes proteolytic enzymes 
will cleaves bony part into calcium, phosphate and collagen (hydroxyprolene). This 
released hydroxyprolene  is  excreted into urine. Elevated hydroxyprolene in the blood 
is the marker of bone destruction. Alkaline phosphatase is the marker of bone 
formation. 
These released calcium and phosphate enters the kidney and freely filtered by 
glomerular capillaries. Parathormone role is kidney is to reabsors calcium and secretes 
phosphates. Normally in proximal convoluted tubules special transport is situated is 
called sodium- phosphate co transporter. This transporter transports phosphates from 
glomerular tubule to interstitium. Paratharmone works on this place to prevent this 
reabsorption. Parathormone G protein coupled receptors stimulated and activates 
adenylcyclase that will produce increased cyclic AMP. This increased cyclic AMP 
produces protein kinase A that will lead to phosphorylation and inhibits the  sodium- 
phosphate co-transporter pump. So phosphate will not reabsorbed and excreted 
through urine.  
Calcium is not reabsorbed in proximal convoluted tubule. So it enters into 
distal convoluted tubule. In distal convoluted tubule there is two pumps are present to 
reabsorb calcium ions. One is calcium ATPase pump another pump is sodium – 
calcium exchange pump. Parathormone G protein coupled receptors  also present on 
distal convoluted tubule. Paratharmone stimulates and activates adenylcyclase that 
will causes  increased cyclic AMP production . This increased cyclic AMP produces 
protein kinase A which enhances the action of both the pumps. By this calcium is 
actively reabsorbed and enters into systemic circulation but phosphate will not. Thus 
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parathormone normally causes hypophasphatemia and hyperphosphaturia and 
hypercalcemia. 
 
 
 
 
 
 
 
Role of vitamin D:  
Normally in skin cholesterol is stored in the form of 7 dehydrochlolesterol. 
After sunlight this 7dehydrochlolesterol is converted into cholecalciferol. This 
cholecalciferol is inactive form. Then it is transported into systemic circulation and 
reaches liver. Liver produces hydroxylation in 25
th
 position of cholecalciferol and 
produces 25 hydroxy cholecalciferol. This form is also an inactive. Finally it reaches 
the kidney. In kidney another  hydroxylation occurs at 1 st position and makes the 
compound into 1,25 dihydroxy cholecalciferol, which it is the active form. Vitamin D 
increases both serum calcium and serum phosphate level. Normally serum calcium is 
absorbed in GI system. This absorption is controlled by a protein called calbindin.  In 
hypocalcemic states paratharmone also activates vitamin D. this vitamin D enters in 
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Gl system and binds with vitamin D receptor  translocates into  nucleus and produces 
mRNA which produces more and more amount of calbindin protein. This elevated 
calbindin protein absorbs more and more calcium and raises the serum calcium level. 
Vitamin D also increases  the reabsorption of phosphates from GI system. So the net 
effect of vitamin is hypercalcemia and hyperphosphatemia.  
Calcium and diabetes: 
Ca2+ ions modulates the secretion of insulin to elevated blood sugars.  Calcium 
alters  diabetes regulation by acting on GLUT 4 receptors. Insulin is normally stored 
in secretory granules which is present in the pancreatic beta cells. The release of 
insulin is mainly depends on the influx of calcium ions  through voltage-gated calcium 
channels which is present in the beta cell membrane of pancreas. Because  of  insulin 
plays s key role in  blood glucose regulation a small change in the calcium influx into 
the cells, alterations in the calcium flux has adverse events  on beta cell secretory 
function and increase the risk of development of diabetes.(2) Increased cytosolic 
calcium concentrations in L6 myotubules leads to activation of GLUT4 transporter 
expression and an increase in insulin-stimulated glucose transport activity. calcium 
regulates GLUT4 transporter  expression in a time- and dose dependent manner  
which  occurs in C2C12 myotubules.(3) AMPK-induced GLUT4 expression is 
blocked by elevated cytosolic calcium in chronic conditions. And also  increase in 
intracellular calcium levels  decreases the effect of insulin in adipocytes. This effect is  
due to the reduced decreased receptor activity and also decreased number of GLUT 4 
receptors. Obviously  increased calcium levels decrease the expression of GLUT4 
transporters and it leads to decrease glucose uptake and finally it produces elevated 
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blood sugars in serum. Incidence of diabetes mellitus in primary hyperparathyroidism 
is approximately 9%. And incidence of primary hyperparathyroidism in diabetes 
mellitus is around 2%.  In type 1 diabetic  patients, a elevated serum calcium level is a 
risk factor for autoimmune hyperparathyroidism  which is associated with production 
anti calcium sensing receptor autoantibodies. In diabetic ketoacidosis conditions, 
severe hypovolemic condition leads to hypercalcemia. Metabolic acidosis and bone 
resorption leads to insulin defiency. Insulin growth factor-1 deficiency and 
hypophosphatemia are potential factor for hypocalcemia. 
Diabetes with hypocalcemia : 
Diabetes  mellitus  patients  has increased risk of d acute renal failure because 
of  volume depletion. In renal failure conditions phosphates will not be excreted by 
kidney. An calcium is also not reabsorbed by distal convoluted  tubules of nephrons. 
Phosphates also binds with ionized calcium and removes calcium from the blood 
circulation. So chronic renal failure is associated with hypocalcemia, 
hyperphosphatemia, hypercalciuria and vitamin D also due to inefficient production of 
1 alpha hydroxylase enzyme. Diabetes is also produces hypomagnesemic effect. 
hypomagnesemia produces causes impaired secretion of parathormone through bone 
and renal tubular resistance to the action of parathormone. Vitamin D deficiency and  
diuretics use  mainly  furosemide produces  hypocalcemia. In diabetic patient  
decreased parathyroid gland responsiveness to hypocalcemia will occur. 
hypoalbuminemia is associated  with pseudo hypocalcemia  due to  Ionized calcium 
binds to negatively charged sites on albumin. So that reduction of  total serum calcium 
concentration occurs  even though there is  normal ionized calcium levels in serum. 
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Calcium and lipid metabolism: 
          Lot of mechanisms have been identified to explain the relationship between 
calcium, lipids, and estrogens.(4) In premenopausal women estrogens  neutralize the 
adverse effect of serum calcium on lipid metabolism. Many trials are concluded that  
in estrogen deficient state calcium supplementation  contribute to increase serum 
cholesterol by reduced hepatic clearance. In normal situations estrogens activates 
LDL-cholesterol receptor thereby increases cholesterol degradation in liver. But serum 
calcium decreases cholesterol degradation and it also stimulates lipidssynthesis in 
body.  7alpha hydroxylase enzyme is involved in the cholesterol metabolism. Calcium 
supplementation decreases the activity of that enzyme thereby increases serum 
cholesterol levels. Calcium also stimulates Sterol Regulatory Element- Binding 
Protein (SREBP)-1c expression in fatty acid synthesis. This SREBP- 1c is a 
transcription factor involved in de-novo synthesis of fatty acids. SREBP pathway also 
plays a important  role in theregulation of HDL-cholesterol metabolism in our body. 
In men and premenopausal state Estrogens prevents cholesterol increase by 
neutralizing the calcium. So the  postmenopause state is more critical for some reasons 
because  many features of metabolic syndrome, including central obesity, altered lipid 
metabolism, insulin resistance, and systemic hypertension will occurs. These 
abnormalities may be due to 1.  ovarian failure 2. central fat redistribution associated 
with estrogen deficiency.(5)  Hormone replacement therapy will produce beneficial 
effect on lipid metabolism in postmenopausal state. Nowadays many trials proved that  
the combination of calcium supplementation and estrogens deficiency will affect the  
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lipid profile that leads to cardiovascular risk. Post menopause women have the worst 
lipid  profile that is associate with higher serum calcium level.(6) 
Calcium and contraction in cardiac muscle : 
        Calcium is the important ion for contraction of cardiac muscle. In cardiac muscle 
calcium is highly stored in sarcoplasmic reticulum. This calcium is released from SR 
by active process. Apart from this many receptors and ion channels are present in 
sarcolemma that are participates in calcium regulation system. The released calcium 
from sarcoplasmic reticulum activates actin myosin compenent and leads to muscle 
contraction. This process not only depends the calcium channels and calcium 
transporters but also  the precise locations and spatial arrangement of calcium. The 
depolarization occurs in neuro muscular junction. cardiac pacemaker opens L-type 
(longitudinal type)  Calcium channels which are  situated in the surface membrane. 
The entry of a small amount of Calcium resulting  large increase of calcium  in the 
dyadic space- the area bounded by the transverse tubule and sarcoplasmic reticulum of 
cardiac myocyte. Ryanodine receptors normally situated in the membrane of 
sarcoplasmic reticulum. The increase of calcium in dyadic space will leads to 
confrontational change of ryanodine receptors and calcium is released from 
sarcoplasmic reticulum through the ryanodine receptors. This process is also called as 
calcium induced calcium release.(7) 
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Figure showing the calcium influx and efflux during excitation contraction 
coupling 
Transverse Tubules  
Transverse tubules  or T tubules are the deep invaginations of the  sarcolemma. 
voltage-gated  calcium channels are highly present in the T tubules. This T tubules are  
tightly coupled with ryanodine receptors of the sarcoplasmic reticulum. This forms the 
dyadic space with SR. dyadic space calcium change leads to calcium release  from the 
sarcoplasmic reticulum. In heart failure conditions the ultra structure of T tubule is 
altered. Because of this structure alteration, the Transverse tubules become separated 
from the sarcolemma and leaves the ryanodine receptor orphaned that impairs calcium 
induced calcium release. Dyadic space calcium transits mainly depends on calcium 
diffusion. The altered T tubule structure leads to dys synchronous Ca2+ transits that 
causes poor excitation  contraction coupling that is the trigger for arrhythmic activity.  
Junctophillin is the protein maintains the architecture of transverse tubules. Many 
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studies concluded that disruption of junctophillin leads to cardiac hypertrophy and 
ventricular arrhythmias. Beta adrenergic blockers and sildenafil reduces the disruption 
of alteration of t tubule architecture. 
The magnitude of calcium rise is not only depends ryanodine receptors and 
calcium in transverse tubules but also the calcium binding buffers and mitochondria.  
For systolic contraction calcium is needed in cytoplasm in higher level. For diastolic 
relaxation calcium should be low in cytosol. This can be maintained by influx-efflux 
mechanism. For influx of calcium ryanodine receptors plays a major role. For the 
efflux property two buffers are needed. They are SERCA (Sarco/endoplasmic  Ca-
ATPase ) and sodium–calcium exchange (NCX)  channel.  SERCA causes calcium 
efflux by moving the calcium ions into the sarcoplamic reticulum.  Sodium–calcium 
exchange (NCX)  channel reduces the cytosolic calcium  by pumping the calcium out 
of the cell. Apart from this two major mechanisms, the  increased cytosolic calcium 
inactivates the L type calcium channels which are present in the membrane of cardiac 
cell. All these three events  continues till the calcium influx and efflux are equal in 
cytosol. 
The  inward current from neuro transmitter signal  depolarizes the cell 
membrane and immediately  opens voltage-gated  sodium channels.  Because of this 
opening large amount of inward sodium current will occur. The inward sodium 
current depolarizes the cell membrane. This depolarization reaches the  cell membrane 
potential which is permissible for opening  of  voltage gated calcium channels. 
Opening of calcium channels leads to inward flow of calcium ions. This long standing  
inward current is  responsible for plateau phase of myocardium. 
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 The released calcium from sarcoplasmic reticulum binds with troponin C. 
tropomyosin are integral  component of actin. The actin binding protein is the protein 
which binds the tropomyosin to actin with van der wal forces. Because of this 
interaction myosin  cannot be bind with actin. Calcium removes the tropomyosin from 
the actin filament and enhances the binding of myosin and Facilitates formation of 
cross bridges between actin and myosin that finally leads to  myocardial contraction.   
Inward calcium current is  inactivated  by voltage gated calcium channels  and the   
simultaneous opening of voltage-gated potassium channels that allows action potential 
repolarization, that is needed for ventricular relaxation. Ventricular  relaxation  mainly 
depends on a decrease in inward  flow of calcium current  that is permissible  for 
unbinding  cross-bridges. Sodium calcium exchanger exchanges 3 sodium for only 
one calcium it produces  net positive charge. 
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Cardiac hypertrophy: 
           If  the heart faces any hemodynamic stress or burden  it compensates the stress 
by three mechanisms. The important mechanism is augmentation of cardiac muscle 
mass to bear extra work load. Other mechanisms are neurohormonal and excessive 
cross bridge formation as per frank starling mechanism. The neurohormonal 
mechanism is deleterious if continued prolonged time. Excessive cross bridge 
formation mechanism has limited in  scope, and the it is also deleterious as a chronic 
adjustment. So the increasing cardiac muscle mass has a major role in the 
compensation for hemodynamic burden or overload. Cardiomyocytes are become 
terminally differentiated soon after birth. Because of this increased work load,  
hypertrophy occurs in  already existing muscle. Two types of overload occurs to 
compensate the load. One is pressure overload and another one is volume overload. In 
pressure overload conditions like systemic hypertension and aortic stenosis, 
sarcomeres are added in parallel direction that leads to increased width of myocyte 
and causes ventricle wall thickness augmentation. This remodeling effect of heart is  
also called as concentric hypertrophy.(8) 
In volume overload conditions like chronic mitral regurgitation,  chronic aortic 
regurgitation and severe anemia  addition of sarcomere in series leads to myocyte 
lenghthening that  also increases the ventricular volume.(9) This pattern of cavity 
dilatation with a decrease in ratio of wall thickness is called eccentric hypertrophy. In 
initial stages, the eccentric hypertrophy is also compensatory mechanism to alleviate 
the cardiac burden. But in long term eccentric hypertrophy is sometimes deleterious 
because it increases the risk of ventricular arrhythmias and left ventricular failure.(10) 
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Pathogenesis of ventricular remodeling : 
Many  studies proved that a mechanical signal initiates the biological events  
that leads  to coordinated cardiac muscle growth. So the signals for volume overload 
and pressure overload are different. In pressure overload myosin heavy chain 
synthesis increases by 38% within hours. This augmentation is mediated by an 
increase in translational efficiency of biological signal modulators. But in volume 
overload myosin heavy chain degradation rate is decreased that increases left 
ventricular muscle mass. Changes in radius, feedback loop, thickness, and pressure  all 
are regulates the mechanical signal. If these factors modulates regularly and correctly 
hypertrophy will be typical. If large myocardial infarction occurs which imposes a 
eccentric hypertrophy on the remaining myocardium that leads to ventricle dilatation 
and increase in LV mass. Even though the initial dilatation is compensatory to 
maintain the ejection fraction, adverse remodeling will develops. Because of this 
remodeling the ventricle becomes more spherical and ventricular wall stress will 
become increases. In concentric hypertrophy wall stress is subnormal, and ejection 
fraction is normal or supernormal. Both concentric and eccentric hypertrophy are 
usually accompanied by gene reprogrammig complex change. The changes are the re-
expression of immature fetal cardiac genes like (a) genes that modify motor unit 
regulation and composition (b) energy metabolism modification genes (c) hormonal 
pathways encoding genes (eg, ANP, ACE). The parasympathetic and sympathetic 
receptors are down regulating the beta 1-adrenergic receptors and M2 muscarinic 
receptors. Increased ratio of angiotensin II to Angiotensin 1 receptor subtypes also 
plays important role. (11) 
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The physiology of hypertrophy is an increase in the number ofsarcomeres 
which are force-generating units of myocyte. The mechanical input like pressure or 
volume is transduced into a biochemical event. This activated biochemical event by 
calcium calmodulin pathway causes activation calcineurin. This calcineurin modifies 
gene transcription factors like NFAT in the nucleus. The important transducer is focal 
adhesion complex and integrins that connect the internal cytoskeleton of the cell to the 
extracellular matrix. Multiple tyrosine-phosphorylated kinases and serine-threonine 
kinases like calcinuerin are implicated in the signaling pathway of hypertrophy. The 
disruption of cell-cell and cell-ECM contact is sufficient to modulate both cell growth 
(hypertrophy). In chronic hypertrophy situation changes in integrin expression and  
integrin shedding into adjacent extra cellular matrix  raises the potential for disordered 
biomechanical signal transduction for suboptimal myocyte growth. In animal models 
acute biomechanical signal transduction is accompanied by recruitment of the G-
protein–coupled neuro hormones like angiotensin II and endothelin- 1. 
In clinical medicine neurohormonal signaling molecule serves as a master 
switch for ventricular hypertrophy. Many trials shows that via the AT1receptor,  
angiotensin II plays a important  role in induction of hypertrophy. Angiotensin II  can 
directly induce the molecular events of cardiac myocyte growth and it is required for 
the growth of stretched neonatal myocytes. After a vast search for a signaling 
molecule for cardiac hypertrophy recently identified  molecule is  calcineurin. It is a 
calcium calmodulin-dependent phosphatas. In transgenic mice over expression of the 
calcineurin signaling pathway produces hypertrophic change that will  be suppressed 
by pharmacological agents called  calcineurin inhibitors. But calcineurin inhibitors are 
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fail to suppress hypertrophy in humans with hypertension after cardiac transplantation. 
Many experimental animal and human observations suggest that thousands of  
signaling pathways  modulates cardiac hypertrophy, with the potential for recruitment 
of an  alternate signaling pathway when  any single pathway is inactivated. 
Hypertrophy and Connective Tissue 
In cardiac hypertrophy to support an increased pressure or volume overload  
myocytes are accompanied by increases in the surrounding structures of connective 
tissue and ground substances well as the capillary and nerve networks in a coordinated 
manner. The connective tissue  is primarily made up of collagen and also less amount 
of elastin, fibronectin and laminin.  All 4 types of collagen present in myocardium. 
Within that 85% of total collagen is made up of type 1 collagen in myocardium. The 
collagen complex provides a mechanism for translation of  individual myocyte force 
generation into contraction of left ventricle. It prevents the development of edema, and 
it is responsible for the ventricular stiffness during diastole. In pressure-volume 
overload hypertrophy, increase collagen production that occurs to adapt the overload 
state. It is different from pathological collagen deposition. In pathological state 
collagen deposition occurs in both perivascular and interstitial area leads to fibrosis. In 
severe chronic hypertension and aortic stenosis  patients biopsy studies shows changes 
in collagen architecture and  severe fibrosis involving in myocardium. Sometimes it 
can reaches upto 30%. 
Role of Metalloproteinase:  
In volume overload hypertrophy extracellular matrix remodeling is somewhat  
different. In volume hypertrophy conditions the occurance of ventricular cavity 
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dilatation is due to both myocyte elongation and changes in collagen cross-linking. 
collagen weave dissolution leads to increased elasticity,  increased muscle fiber 
slippage, and an increase in ventricular chamber size. This dissolution is mainly due to  
activation of matrix metalloproteinase (MMPs). This MMPs is a family of zinc-
containing proteins which contains collagenases, stromalysins and gelatinases. Animal  
models and human end-stage dilated cardiomyopathy shows that an increased 
metalloproteinase activation in biopsy results. Increased MMPs activation down 
regulation of localized tissue inhibitors is important for collagen matrix changes that 
allows ventricular chamber enlargement. But MMPs does not have any role in 
development of concentric hypertrophy.(15) 
Echocardiographic Diagnosis of LVH - 
Pathological hypertrophy symptoms will not manifests for longer time unless 
congestive cardiac failure occurs. Sometimes it leads to sudden cardiac death without 
any symptom. To detect that left ventricular hypertrophy non invasive 
echocardiographic examination is very important. 2D dimension echocardiography 
measures the M mode left ventricle dimension and left ventricular mass. Pathological  
left ventricular hypertrophy  requires adjustments for sex, height, weight, and body 
surface are. This LV mass is calculated by a formula which includes left ventricular 
end diastolic dimension, inter ventricular septal thickness and posterior wall thickness. 
Relative wall thickness is the another factor which is calculated by 2×posterior wall 
thickness. By using body surface area left ventricular mass can be converted into left 
ventricular mass index. Relative wall thickness tells about the nature of hypertrophy.  
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Left ventricular mass (LVM) 
Is  calculated by a special formula called  
Devereux formula :  
LV mass (g) = 0.8 {1.04 x (LVDD + IVS + PW)³- (LVDD)³} + 0.6 
 
LVEDD -left ventricular end diastolic dimension 
PWTD - posterior wall thickness at end diastolic 
IVSd - inter ventricular septum thickness at end diastolic 
LVM index (LVMI) was calculated by correcting left ventricular mass for body 
surface area. 
LVH is diagnosed as if LVMI > 115 in men and LVMI > 95 in women. 
If relative wall thickness and left ventricular mass index is normal that LV geometry is 
called as normal. Increased relative wall thickness and normal left ventricular mass 
index called concentric remodeling. Eccentric hypertrophy is defined as increased 
relative wall thickness and increased left ventricular mass index. 
Mechanism of Diastolic Dysfunction in cardiac Hypertrophy: 
In LVH, abnormalities occurs in both active and phase  and passive filling 
phase of ventricular relaxation. During myocardial relaxation cross bridge dissociation 
occurs after systolic contraction that is  modified by pressure or volume overload. 
During diastole period the rapid reduction of cytosolic calcium to basal levels 
occurs. Intracellular pH changes the myofilament sensitivity to calcium ions. The 
ATP-dependent sarcoplasmic reticulum channels moves intracellular calcium into the 
sarcoplasmic reticulum against a concentration gradient that leads to rapid fall of 
cytosolic calcium. Phospholamban  is a SERCA inhibitor which is activated only 
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dephosphorylated state.  During depolarization calcium extrusion occurs in very 
slower phase. This activity is mainly depends on the low affinity and high-capacity 
sarcolemmal Sodium calcium exchanger pump. The SERCA-2 down regulation is 
usually ubiquitous in many trials of advanced volume and pressure overload 
hypertrophy. Some trails evidenced that changes in SERCA-2 levels have the potential 
efficacy to modify the time course of the calcium transport, cardiac relaxation. 
Anyway the marked reductions in SERCA-2 leads to compensated hypertrophy. And 
it also leads to end-stage dilated cardiomyopathy that is  associated with impaired 
relaxation and also poor systolic performance. In dilated cardiomyopathy patients, 
levels of SERCA-2 are severely reduced that will be partially compensated by 
increased sodium calcium exchanger. Inspite of all these factors some other 
adaptations also occurs to modify the cross bridge attachment and myocardial 
relaxation phase. That  adaptations are increased b-myosin ATPase activity, troponin 
subunit isoform expression changes, phosphorylation, and phospholamban changes. 
Normally myocardial relaxation properties are calculated  by alternate measurements 
of the first derivative of LV pressure decay (2dp/dt).(16) And it also calculated by the 
time course of LV pressure decay between aortic valve closure and mitral valve 
opening. These measurements provide clues to the presence of impaired left 
ventricular  relaxation. But it has some limitation in severe  heart diseases due to those 
cardiac diseases has isovolumic  pressure decay. 
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Diastolic Filling 
The passive deformation properties of the myocardium, including the thickness 
of ventricular  wall and its composition, mainly  collagen deposition architecture and 
active ventricular relaxation influences the passive LV filling and relationship 
between diastolic volume and pressure. The hypertrophied cardiac myocyte  has only 
limited role in increased ventricular stiffness. Trans mitral valve flow velocity curves 
explains ventricular diastolic filling  and left atrial emptying which can be assessed by 
2 D echocardiography technique. Radio nucleotide ventriculography  is an another 
technique used to estimate the rates of active  and passive ventricular filling.  pressure 
gradient across the mitral valve is determined by  left atrial pressure and the active fall 
of LV pressure to its nadir during ventricular relaxation period. This trans mitral 
pressure gradient is directly related to diastolic ventricular filling just after mitral 
valve opening.(17) 
Progressive diastolic dysfunction is assessed by Doppler flow velocity curve. 
Three types of curves are identified during ventricular filling phase. These curves are  
classified by E/A ratio. Type 1- slow relaxation, type 2- pseudo normalization. Type 
3- restrictive pattern. In type 1 early diastolic inflow velocity is reduced. It is 
associated with compensatory increase in filling due to left atrial contraction. This 
produces decreased E/A ratio in ECHO. In type 2 normal E/A ratio occurs. This is due 
to preserved ratio of the of early diastolic filling and atrial contraction. But a rapid 
deceleration of early mitral inflow occurs in ventricular filling phase. This is called 
pseudo normalization. In type 3 all ventricular filling occurs explosively in early 
diastole period  it is associated with a very short deceleration time. This  is suggestive 
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of a high left atrial pressure because of stiff left ventricle. This type is called 
restrictive pattern in echocardiography. Type 3 is associated with severe left 
ventricular dysfunction.  This is assessed by clinically as S3 gallop. It is the 
auscultatory marker of abrupt cessation of ventricular filling during  early diastole 
period  and  increased left atrial regurgitation flow into the pulmonary circulation. 
This finding is also present is many volume overload states like pregnancy and 
exercise.     
In athletes with mild hypertrophy there is no evidence of  systolic contractile 
dysfunction. In pressure overload hypertrophy like aortic stenosis and hypertension  
conditions the hemodynamic hallmark is  elevation the of left ventricle  end diastolic 
pressure but  a normal or relatively small  left ventricular diastolic cavity volume. This 
decreased ventricular diastolic distensibility is related to altered passive properties that 
leads to high myocardial stiffness. Slowed isovolumic LV pressure decay and slowed 
early diastolic mitral inflow velocity and ventricular filling leads to decreased E/A 
ratio is described in many trials. In patients with advanced hypertrophy, this pattern 
may evolve into  more severe abnormality of  restrictive pattern of diastolic filling 
phase. 
In many patients with aortic stenosis and aortic regurgitation states both 
hemodynamic and autopsy reports suggest that the prolongation of ventricular 
relaxation period is closely related to the severity of hypertrophy. But abnormal 
increases in myocardial stiffness are related to collagen architecture changes. 
Ventricular relaxation phase abnormalities and passive myocardial stiffness 
occurs before the alterations in systolic dysfunction. 
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Influence of Age and Sex in Diastolic Function in LVH patients: 
Concentric LVH is common in elderly patients with isolated systemic 
hypertension.  Diastolic dysfunction like impaired relaxation has been observed in 
70% of older patients with  hypertension.  In patients with severe aortic stenosis, sex 
factor greatly  modulates  the pattern of hypertrophic growth of cardiac muscle and 
diastolic function of heart. By using hemodynamic studies analysed by morphometric 
analysis of ventricular autopsies shows elderly patients had severe cardiac 
hypertrophies and interstitial fibrosis.(12) In elder population more severe impairment 
of ventricular relaxation, myocardial stiffness, and filling defects occurs. Left 
ventricular ejection fraction and mid systolic wall shortening were similar in all age 
groups. In aortic stenosis and similar aortic valve disease conditions  men are more 
likely to have cavity enlargement, a lower ejection fraction, trans valvular gradient.  
Men compared to women has increased diastolic myocardial stiffness and more 
collagen architecture changes. (13) 
Prognosis of cardiac Failure due to left ventricular Diastolic Dysfunction : 
Not only systolic dysfunction but also diastolic dysfunction causes cardiac 
failure due to impaired relaxation. This impaired relaxation leads to increased left 
atrial pressure that will increases pulmonary capillary wedge pressure. This may 
present as acute heart failure. Sometimes chronic diastolic dysfunction leads to severe 
pulmonary hypertension that will finally leads to right heart failure that produces 
congestive signs and symptoms. In patients with chronic left ventricular failure  
associated with diastolic dysfunction with normal ejection fraction both male and 
female patients will develops episodic severe congestive cardiac failure and needs 
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intensive care management.(14)  Even in patients with milder degrees of ventricular  
hypertrophy with diastolic dysfunction, an inability to improve LV volume during 
exercise. Even though the heart failure patients with preserved  ejection fractions had 
a lower mortality risk compared with patients with reduced ejection fractions heart 
failure patients with preserved  ejection fractions had 20 % mortality rate annually. In 
patients with in  LVH & diastolic dysfunction atrial fibrillation also have a major role. 
The increased reliability on atrial contraction against stiff left ventricle needs to 
improve the cardiac output. In patients with atrial fibrillation will make poor cardiac 
output and it is poorly toleratable.  In pressure overload conditions hypertension is 
responsible for atrial fibrillation in 16% patients than other risk factors. This atrial 
fibrillation leads  5 to 6 fold increase of stroke risk . 
Mechanism of Systolic Dysfunction: 
Changes in cardiac cellular biology leads to systolic dysfunction is very 
complex and it is not due to a single change in gene expression. Sub endocardial 
ischemia due to chronic pressure overload or extreme volume overload plays  
important role in systolic dysfunction. This subendocardial ischemia limits exercise 
reserve volume and promotes myocardial fibrosis. Excessive afterload due to 
inadequate hypertrophy to normalize the ventricular wall stress itself suppresses 
systolic stroke volume independent of intrinsic changes in myocardial contractibility. 
This  effect accounts for the drastic  improvement in ejection performance after valve 
replacement in aortic stenosis and aortic regurgitation patients. Important mechanism 
for reduced myocardial contractility at the level of the myocyte is impaired calcium 
homeostasis. This calcium homeostasis abnormality leads to the depression of the 
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force-frequency  relationship,  motor unit composition change,  and  relative increase 
in b-myosin heavy chain that  occurs in both human and animals. The  densification of 
the microtubules within the cardiac myocyte, which causes an improved internal load 
on sarcomere length shortening. Many  assessment regarding LV midwall shortening 
using 2 D echocardiography allows the identification of impaired ventricular 
contractile function. It also useful in some patients in whom the geometric changes of 
concentric remodeling supports normal ejection performance. In volume overload 
hypertrophy myofibrils loss will occurs. Complex changes in energy metabolism due 
to loss of myofibrils may reduce  the capacity to maintain the levels of free energy at 
ATP hydrolysis. This ATP is needed for optimal functioning of  both the motor unit 
and the membrane pumps that is required for many ion homeostasis. Apoptosis may 
cause a repetitious low frequency loss of myocytes in the hypertrophied myocardium  
that would  increase the biomechanical load on the remaining normal myocytes.  In 
early stages of pressure overload conditions before the development of adaptive 
hypertrophy, low frequency of apoptotic cardiac myocytes are identified. 
Prevalence of apoptotic myocytes are wildly variable in many studies of end-
stage dilated cardiomyopathy. 
Vascular calcification by calcium: 
Apart from calcineurin calmodulin pathway many other biological mechanism 
are discovered  for calcium induced cardiomyopathy.  Calcium  exert harmful impact 
on cardiovascular health  by vascular calcification. Calcium phosphate deposited in 
cardiovascular structures in elevated serum calcium levels. Newer studies concluded 
that calcification of coronary arteries leads increased risk of atherosclerotic plaque 
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that finally causes coronary ischemic.  In patients with chronic renal disease, daily 
ingestion of Calcium supplementation has proportional correlation coronary artery 
disease. In addition to that calcifications, increased serum calcium leads increased 
blood coagulation profile and high arterial stiffness that are positively correlated with 
hypercoagulable state that finally leads to myocardial ischemia that eventually leads to 
cardiomyopathy and heart failure. This increased coagulation profile also leads to 
thrombus formation in many organs including  brain, spleen and mesentry. 
Impaired calcium efflux during Diastole : 
To start ventricular relaxation, cytosolic calcium must be effluxed into  
Sarcoplasmic reticulum by SERCA or out of the cell by sodium calcium exchanger. 
Diastolic  The sarcomere is the functional force of cardiac muscle.  cardiac failure is 
produced by spontaneous release of calcium during diastole  leads  to spontaneous and 
highly variable diastolic sarcomere contractions that finally leads  to loss of systolic 
function also. Calcium uptake by sarcoplasmic reticulum is reduced by reduced 
expression and activity of SERCA.(18) And reduced calcium uptake by sarcoplasmic 
reticulum  due to increased inhibitory action  of phospholamban. In  dephosphorylated 
form Phospholumban inhibits SERCA activity. In phosphorylated form, the 
phospholumban assembles in a pentamer structure that lacks SERCA inhibitory 
activity. Many studies proved that phosphorylation of PLN is decreased in diastolic 
heart failure. Increased dephosphorylation of phospholamban is achieved by increased 
calcineurin activation. Some times mutation in PLN gene (R9H, R9L) leads to 
constant de phosphorylatation that leads to increased SERCA inhibition. The 
phenotypes of R9H carrier will develop dilated cardiomyopathy and premature  
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cardiac death. Another new regulator for SERCA activity is Histidine rich calcium 
binding protein (HRC). HRC is low affinity at the same tie high capacity binding 
protein which is present in sarcoplasmic reticular lumen. It binds with triadin and 
inactivates ryanodine receptor. This HRC mediate a cross-talk between  Sarcoplasmic  
reticulum calcium release and uptake.  HRC  is also inhibit the SERCA that is  
strongly associated with ventricular arrhythmias in dilated cardiomyopathy subjects 
due to low calcium release and prolonged efflux time. 
Mitochondrial Calcium regulation : 
    Mitochondria consists approximately 25% to 35% of cardiac mass. 
Mitochondria is very essential for providing ATP to meet the energy demand of 
cardiac muscle function. Calcium is the important messenger for communicating 
cellular energy demands to mitochondria. Oxidative phosphorylation is a Calcium 
regulated process.  Calcium  increases the tricarboxylic acid dehydrogenases activity 
which is  involved in the production of NADH/NADPH. The inner mitochondrial 
membrane contain aspartate/glutamate exchangers. It contains calcium binding 
proteins that facilitates the ATP production in response to calcium signal. 
Mitochondriahas a lower affinity but a higher capacity for calcium uptake.  
Mitochondria also contains calcium buffer which is activated according to cytosolic 
calcium. Excessive accumulation of mitochondrial calcium leads to mitochondrial 
death by increased oxidative stress and apoptotic mediators like cytochrome C. 
Mitochondria is the important source for pathological increases of reactive oxygen 
species. This ROS produces oxidative stress which damages the mitochondrial DNA 
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and proteins that finally leads to mitochondrial dysfunction. This impaired 
mitochondrial bioenergetic function leads to heart failure.  
Calmodulin: 
 
 
 
 
 
 
Many  proteins are sensitive to serum calcium levels mainly in cellular level. 
The important proteins are protein C and Calmodulin.  A Small dumbbell-shaped  
Calcium  modulated protein is  called as calmodulin. It is highly present in the 
cytoplasm of all mammalian cells. It   acts as an intermediary protein that senses 
calcium levels and relays signals to various calcium-sensitive enzymes, ion channels 
and other proteins. It is composed of  two globular domains which are connected 
together by  flexible linker and those  ends binds with  two calcium ions. Troponin  C 
and calmodulin are structurally  similar  but the difference between these two protein 
is length of the linker  which connecting the two calcium-binding globular domains. 
Calmodulin’s target protein are present in different size and shapes an sequences. This 
calmodulin also binds with phosphatases and kinases and activates it. These enzymes 
are important in cell signaling, cell death and cell transport. After binding of calcium 
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non-polar surface of calmodulin is exposed and then it binds to non-polar regions on 
the target proteins of the cell. 
Even though calmodulin is not bound to its target proteins the connector 
between the two calcium binding globular domains is usually flexible. This  
Calmodulin typically wraps around its target with the two globular domains gripping 
each side. Calmodulin contains nearly four identical high-affinity calcium binding 
sites. The calcium-binding site is composed of a characteristic loop flanked by two 
alpha helix. The positively-charged calcium ion is surrounded in the loop by  one 
glutamate  and three aspartates which are negatively-charged side chains and one 
oxygen atom from the backbone of the protein chain 
Calcineurin 
 
 
 
 
 
 
 
 
 It is a calcium-calmodulin dependant serine -threonine protein  phosphatase. 
Calcineurin  has two sub units  
1. Calcinuerin A - 61 Kd -calmodulin binding catalytic subunit. 
2. Calcineurin B – 19 Kd – calcium binding regulatory subunit 
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Function:  
Calcineurin is activated once calcium-calmodulin complex activated. This 
activated calcineurin induces NFATs. In resting state NFAT will be in phosphorylated 
form. Calcineurin changes the NFAT from phosphorylated into dephosphorylated 
form and this NFAT induces DNA transcription of cell. 
Because of low intracellular calcium level, very minimal amount of calcineurin 
is activated. If extracellular calcium rises or if there is any defect in voltage gated 
calcium channels it will leads to more influx of calcium from extracellular into 
intracellular space that leads to exaggerated activation of NFAT by calcium 
calmodulincalcineurin pathway. This effects will cause pathological effect. The 
calcineurin is useful for the biosynthesis of neurotransmitters and transport of this NT 
substances in synaptic terminals of brain, myocardium, skeletal muscles and kidney. 
Defective calcineurin pathway leads to mental retardation, down syndrome,  
Alzheimers  disease, brain hypoxemia and cardiac hypertrophy. 
In myocardium calcineurin- NFAT signal pathway is activated only when there 
are pathological increases in serum calcium. This pathway is not activated during 
pregnancy or exercise which produces physiologic hypertrophy. 
In transgenic mice calcineurin was found  as a hypertrophic signaling factor 
based on its over expression in the heart.  These transgenic  mice  expresses an 
activated mutant of  calcineurin which is  demonstrated a profound hypertrophic 
response  that rapidly progresses  into dilated left ventricle and leads to heart failure 
with in a short duration 2-4 months. Many newer trials shows that  calcineurin is a 
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sufficient inducer of the hypertrophic response. Like that many groups  reported that  
increased cardiac calcineurin activity in hypertrophic hearts. increase in cardiac 
calcineurin  activity  leads to salt-sensitive hypertension induced cardiac hypertrophy , 
infrarenal aortic constriction-induced neuro endocrine-mediated hypertrophy and  
steroid induced cardiomyopathy . 
Calcineurin inhibitors: 
Commonly used calcineurin inhibitors are cyclosporine and tacrolimus. 
Cyclophilin is an immunophillin class of protein present inside the cell. 
Cyclosporine enters into target cells and attaches into cyclophillin protein. This 
cyclosporine-cyclophillin complex finally binds with calcineurin protein and 
inactivates it. Even though calcium calmodulin complex overexpressed in the cells 
calcineurin will not to be activated. This leads to failure of transcription. Calcineurin 
inhibitors are commonly used for post transplant patients rheumatoid arthritis, uveitis, 
psoriasis, inflammatory bowel disease, bronchial asthma and dermatomyositis. It can 
also useful for aplastic anemia.(19)  
Regulated influx of calcium release is important for the function of muscle 
contraction, fertilization and memory. The calcium calmodulin activated calcineurin 
dephosphorylates and induces the nuclear localization of NFAT transcription 
complexes Which is the cytosolic component. The NFAT transcription complexes 
assembles  in the  DNA and  activates the cell–cell interactions genes.(20)  
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Normally in ligand gated receptors channel activation leads activation of 
phospholipase that will turns into inositol triphosphate. This inositol triphosphate is 
useful for the release of calcium from stored granules. This calcium is insufficient for 
the activation NFAT transcription complexes. So that a special calcium channel is 
activated. That is called calcium release activated calcium channels or CRAC 
channels. This signal is called inside-out  signaling. 
 
 
 
 
 
 
 
 
CRAC channels induced NFAT activation (inside out signal) 
45 
 
In embryonic state  NFATc1 is present  is endocardial cell which is useful for 
the development of valves and  myocardium. During development of heart the  
NFATc1 receptors are restricted to epithelial-to-mescenchymal transformation cells  
which is finally developed into endocardial cushion. This endocardial cushion are 
furtherly differentiates into cardiac valves and septal walls. Many studies proved that 
the  animal models treated with calcineurin inhibitors during embryonic state present 
with mal development of heart and consequently heart failure. Connexin is the protein 
which forms gap junctions which is useful for the transmission of IP3, influx of 
calcium by IP3  and  CRAC channels.NFATc4 is associated with cardiac zinc finger 
factor GATA4. This GATA4 transcription factor is important for cardiac hypertrophy, 
MCIP-1 (multipotent IsL cardiovascular progenitor  gene is activated once calcineurin 
elevation. By feedback mechanism it inhibits the further activation of calcineurin and 
prevents the cardiac muscle hypertrophy. Cabin/Cain, CsA or FK506 also the inhibitor 
proteins of calcium dependant NFAT signal pathway. These analogues will be useful 
to prevent cardiac hypertrophy that process is still in research. 
Types of  NFAT: 
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Transient  receptor potential (TRP) pathway and LVH: 
        Although several Signal transduction pathways are involved in the process of 
cardiac hypertrophy  one more important pathway is transient receptor potential (TRP) 
pathway. The transient receptor potential super family  contains six subfamilies. They 
are more  permeable to calcium ions into the cardiac myocyte. In TRP subfamily, 
especially TRPC3 is increased in cardiac hypertrophy. apart from TRPC3, TRPV2, 
TRPM7, and TRPP2 are also associated with cardiac fibrosis and left ventricular 
hypertrophy. Transient receptor potential vanilloid 3 channel has present in skin 
keratinocytes, dorsal root ganglion, trigeminal ganglion, spinal cord, nasal epithelia 
and also myocardium. TRPV3 channels activation leads to pressure overload 
hypertrophy of  myocardium. Many studies hypothesized that the TRPV3 activation  
could be directly or indirectly involved in cardiac hypertrophy. 
CaMKII and Arrhythmia: 
Arrhythmias are more common in patient with heart failure particularly if 
patient ejection fraction is less than 30%. Arrhythmias leads to sudden cardiac death 
especially ventricular origin. Calcium hemostasis alteration leads to arrhythmias.(21& 
22)  
Increased  oxidant stress,  calcium hemostatsis alteration leads to heart failure 
as discussed above. In this situation calcium dependant calmodulin protein kinase  II 
is activated. 
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This CaMKII makes alteration is voltage gated sodium channels, calcium 
channels and ryanodine receptors that will trigger arrhythmic effect. calcium 
dependant calmodulin protein kinase II causes phosphorylation of voltage gated 
calcium channels at β-subunit receptor level. That will makes increased calcium 
overload that consequently enhances the early after depolarization phase.  
Phosphorylation of ryanodine receptor by CaMKII increases diastolic SR calcium  
leak, that triggers the delayed after depolarization that also proarrhythmic action over 
the voltage gated sodium channels by CaMKII  prolongs the inflow current of sodium 
that makes prolonged action potential finally increases EAD phase. CaMKII inhibition  
prevents ventricular arrhythmias in myocardial tissues which is proved in animal 
model. 
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MATERIALS AND METHODS 
 
 
          This study was conducted in Government Royapettah hospital, Chennai for 
duration of 6 months from April 2018 to Sep 2018. A proper and complete  ethical 
clearance  was obtained from the Institutional Ethical Committee. This  study was 
conducted after getting  a informed consent from all subjects involved in this study.  
 
 STUDY DESIGN  :   prospective cross sectional study 
 STUDY PERIOD  :   six months  (April 2018 to Sep 2018) 
 CONFLICT OF INTEREST : Nil  
 
STUDY POPULATION:  
        Study population consists of diabetic patients  who  attending  medical  out 
patient departments and  admitted as  inpatient in medical ward of Govt. Royapettah 
Hospital. 
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Inclusion criteria :  
Patients with type 2 diabetes  
             Diabetes in this study will be defined by the american diabetes association as 
either 
 Fasting plasma glucose (FBS) of >125 mg/dl or 
 Post prandial blood sugars at 2 hr (PPBS) >200 mg/dl 
Exclusion criteria: 
 Patients with  hypertension 
 On treatment with sulfonylurease 
 A  h/o myocardial infarction, coronary artery bypass or angioplasty, atrial 
fibrillation, moderate to severe valvular heart disease, stroke or occlusive 
peripheral vascular disease, heart failure 
 Serum creatinine> 110 micromoles/ L. ( >1.2 mg/ d L) 
 A history of parathyroid  disease or vitamin D related disorder 
 Medication history including vitamin D, bisphosphonate, estrogen replacement 
therapy and diueretics 
 Uncontrolled thyroid diseases 
 Patient with chronic liver diseases 
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SAMPLE SIZE:  
 
by using  the formula  
prevalance = 4pq/ E² 
 Total number of the subjects – 206 
 95 % confidence interval 
 Level of significance -   p <0.05 
 Assuming power of study – 80% 
 
METHODOLOGY: 
      After obtaining a informed written consent demographic details, past medical 
history  and clinical examination done. Following investigation was done in all 
patients. 
 Serum calcium 
 Serum creatinine, 
 total cholesterol, triglycerides,  
 low density lipoprotein cholesterol ( LDL-C), 
 high density lipoprotein cholesterol (HDL-C)  
 fasting blood glucose 
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 2D ECHO – echocardiography was done in all patients. In left lateral position  
ECHO was performed in parasternal long axis, 4 chamber view. 
  M mode was used to asses the septal wall, posterior wall thickness and left 
ventricular diastolic dimension. 
 By using wall thickness left ventricular mass is calculated. 
 Adjusting the left ventricular mass with body surface area left ventricular mass 
index is calculated. 
 LV mass using the corrected formula 
 
 LV mass (g) = 0.8 {1.04 x (LVDD + IVS + PW)³- (LVDD)³} + 0.6 
 
 LV mass index ( LVMI ): LV mass/ body surface area  
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Results And Analysis 
 
The collected data were analysed with IBM.SPSS statistics software 23.0 
Version. To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & S.D were used 
for continuous variables. To find the significant difference between the bivariate 
samples in Paired groups the Paired sample t-test was used & for Independent groups 
the Unpaired sample t-test was used. The identify the accuracy of the variable the 
Sensitivity, Specificity, PPV and NPV was used. To assess the relationship between 
the variables Pearson's Correlation was used. To find the significance in categorical 
data Chi-Square test was used similarly if the expected cell frequency is less than  5 in 
2×2 tables then the Fisher's Exact was used. In all the above statistical tools the 
probability value .05 is considered as significant level.  
 
  
55 
 
Overall age distribution in the study  
Totally 206 patients are included in this study after exclusion. All patients are 
diabetic patients. Most of the study subjects are with in the age limit of 50-59 years.   
            AGE  
 
Frequency 
 
Percent 
 
 40 - 49 yrs 51 24.8 
50 - 59 yrs 108 52.4 
60 - 69 yrs 42 20.4 
> = 70 yrs 5 2.4 
Total 206 100.0 
 
 
 
  
0.0
10.0
20.0
30.0
40.0
50.0
60.0
40 - 49 yrs 50 - 59 yrs 60 - 69 yrs > = 70 yrs
Overall  age distribution 
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AGE DISTRIBUTION WITHIN LVH AND NON LVH GROUP  
Age distribution in both LVH and non LVH group is compared. 50-59 years  
subjects are more in both groups compared with other age group people. 
                           AGE 
 
Groups 
Total 
Non LVH LVH 
 
40 - 49 yrs 
Count 34 17 51 
% 
within 
Groups 
33.3% 16.3% 24.8% 
50 - 59 yrs 
Count 57 51 108 
% 
within 
Groups 
55.9% 49.0% 52.4% 
60 - 69 yrs 
Count 11 31 42 
% 
within 
Groups 
10.8% 29.8% 20.4% 
> = 70 yrs 
Count 0 5 5 
% 
within 
Groups 
0.0% 4.8% 2.4% 
Total 
Count 102 104 206 
% 
within 
Groups 
100.0% 100.0% 100.0% 
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Overall Gender Distribution 
Number of males are high in overall group compared with females.  
 
Gender distribution in LVH and NON LVH group 
 
 
  
Overall Gender distribution 
Female Male
0%
20%
40%
60%
80%
100%
Non LVH LVH
Gender with Groups 
Female Male
58 
 
Cross tabulation for gender distribution: 
              Gender  
 
Groups 
Total 
Non LVH LVH 
 
F 
Count 47 40 87 
% within 
Groups 
46.1% 38.5% 42.2% 
M 
Count 55 64 119 
% within 
Groups 
53.9% 61.5% 57.8% 
Total 
Count 102 104 206 
% within 
Groups 
100.0% 100.0% 100.0% 
 
By our results left ventricular remodeling occurs mostly in males compared 
with female irrespective of age group. But gender is not make any significant p value 
in LVH occurance. If at all post menopausal women will deveop LVH the occurance 
is very less in females compared with same age group of males. 
Serum calcium level association with LVH 
According to our literature serum calcium is main determinator of left 
ventricular remodeling by many mechanism. Serum calcium is > 10.2 in LVH group 
people. But in non LVH group people serum calcium level is with in normal limit that 
is given as < 10.2 mg/dl. 1 patient in non LVH group is having high serum calcium 
but does not make statistical changes in that group. The mean serum calcium of LVH 
group is 10.6mg/dl 
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           Serum calcium  
 
Groups 
Total 
Non LVH LVH 
 
> 10.2 
Count 0 103 103 
% within 
Groups 
0.0% 99.0% 50.0% 
< = 10.2 
Count 102 1 103 
% within 
Groups 
100.0% 1.0% 50.0% 
Total 
Count 102 104 206 
% within 
Groups 
100.0% 100.0% 100.0% 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
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100%
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Mean, standard deviation of variables in both LVH & non LVH Group: 
The mean age group in  non LVH group people is 52.62 but it is 56.16 years in 
LVH group people. Gender does not make any significance in LVH prevalence. 
Serum calcium level is normal in non LVH group and the mean value is 9.04mg/dl. 
This calcium is high in LVH group people. The mean serum calcium level in LVH 
group peopleis 10.63. The value above 10.2 is considered to abnormal. The mean of 
left ventricular end diastolic dimension, interventricular septal wall thickness, 
posterior wall thickness, and relative wall thickness in LVH group is 52.01, 13.09, 
10.99, 0.4233 respectively. 
The mean left ventricular mass in LVH group is 229.51 but this low in non 
LVH group. After adjusting LV mass with body surface area the mean LV mass index 
in LVH group is 177.38. The mean cholesterol, triglycerides and LDL cholesterol in 
LVH group is 212.70, 159.47, 112.46 respectively. 
  
61 
 
 
 
Groups N Mean 
Std. 
Deviation 
Std. Error 
Mean 
AGE 
Non LVH 102 52.62 5.794 .574 
LVH 104 56.16 6.889 .676 
Sr.Calcium 
Non LVH 102 9.0435 .08905 .00882 
LVH 104 10.6365 .27591 .02706 
LV EDD 
Non LVH 102 45.51 2.362 .234 
LVH 104 52.01 3.823 .375 
IVS d 
Non LVH 102 10.40 .761 .075 
LVH 104 13.09 1.359 .133 
PWd 
Non LVH 102 8.85 .604 .060 
LVH 104 10.99 1.186 .116 
RWT 
Non LVH 102 .3899 .02616 .00259 
LVH 104 .4233 .04514 .00443 
LVMASS 
Non LVH 102 148.23 20.414 2.021 
LVH 104 229.51 61.256 6.007 
LVMI 
Non LVH 102 90.60 12.638 1.251 
LVH 104 177.38 61.697 6.050 
CHOLESTEROL 
Non LVH 102 182.31 30.854 3.055 
LVH 104 212.70 36.546 3.584 
TGL 
Non LVH 102 131.96 31.825 3.151 
LVH 104 159.47 28.298 2.775 
LDL 
Non LVH 102 97.85 21.520 2.131 
LVH 104 112.46 18.140 1.779 
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LVH is diagnosed as if LVMI > 115 in men and LVMI > 95 in women. If 
relative wall thickness and left ventricular mass index is normal that LV geometry is 
called as normal. Increased relative wall thickness and normal left ventricular mass 
index called concentric remodeling. Eccentric hypertrophy is defined as increased 
relative wall thickness and increased left ventricular mass index.  
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T test - to asses the significance of variables : 
In this study t test is used to assess the significance of variables towards the 
development of left ventricular remodeling. The p value is significant if it is <0.01. 
The serum calcium level p value is significant (p<0.005)  in LVH group. It indicates 
the strong association of serum calcium for the development of left ventricular 
remodeling. Age also has significant p value in LVH group. Serum calcium levels are 
increasing in age advances.  Serum cholesterol, LDL cholesterol, triglycerides also has 
a significant p value in LVH group population. But the gender makes any 
significance. The left ventricular end diastolic dimension, septal wall thickness, 
posterior wall thickness also have significant p value. This is the obvious one because 
the determinant of ventricular dimension is by above three parameters. The relative 
wall thickness is also significant in LVH group. But it does not make any change in 
left ventricular mass. It tells about the type of  ventricular hypertrophy whether is it 
concentric or eccentric. 
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Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower 
AGE 
Equal 
variances 
assumed 
6.585 .011 -3.994 204 .000 -3.546 .888 ## 
Equal 
variances 
not 
assumed 
    -4.001 199.379 .0005 -3.546 .886 ## 
Sr.Calcium 
Equal 
variances 
assumed 
146.603 .000 
-
55.540 
204 .000 -1.59301 .02868 ## 
Equal 
variances 
not 
assumed 
    
-
55.982 
124.608 .0005 -1.59301 .02846 ## 
LVMASS 
Equal 
variances 
assumed 
44.423 .000 
-
12.726 
204 .000 -81.284 6.387 ## 
Equal 
variances 
not 
assumed 
    
-
12.826 
126.000 .0005 -81.284 6.338 ## 
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LVMI 
Equal 
variances 
assumed 
94.892 .000 
-
13.922 
204 .000 -86.787 6.234 ## 
Equal 
variances 
not 
assumed 
    
-
14.048 
111.794 .0005 -86.787 6.178 ## 
CHOLESTEROL 
Equal 
variances 
assumed 
3.338 .069 -6.443 204 .0005 -30.388 4.717 ## 
Equal 
variances 
not 
assumed 
    -6.453 199.601 .000 -30.388 4.709 ## 
TGL 
Equal 
variances 
assumed 
.675 .412 -6.559 204 .0005 -27.510 4.194 ## 
Equal 
variances 
not 
assumed 
    -6.552 200.279 .000 -27.510 4.199 ## 
LDL 
Equal 
variances 
assumed 
4.482 .035 -5.272 204 .000 -14.609 2.771 ## 
Equal 
variances 
not 
assumed 
    -5.263 197.002 .0005 -14.609 2.776 ## 
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Correlations
a
 in LVH Groups 
  Sr.Calcium 
LV 
EDD IVS d PWd RWT LVMASS LVMI CHOLESTEROL TGL LDL 
AGE Pearson 
Correlation 
-.087 .063 .021 .049 -.006 .146 -.064 -.139 -.118 -.118 
Sig. (2-
tailed) 
.377 .525 .830 .622 .953 .140 .517 .160 .232 .233 
N 104 104 104 104 104 104 104 104 104 104 
Sr.Calcium Pearson 
Correlation 
1 .022 -.068 .022 .016 -.159 .143 .138 .012 .084 
Sig. (2-
tailed) 
  .826 .492 .826 .872 .106 .147 .164 .906 .394 
N   104 104 104 104 104 104 104 104 104 
LV EDD Pearson 
Correlation 
  1 .267
**
 .373
**
 -.318
**
 .495
**
 .654
**
 .062 -.147 -.101 
Sig. (2-
tailed) 
    .006 .000 .001 .000 .000 .530 .138 .307 
N     104 104 104 104 104 104 104 104 
IVS d Pearson 
Correlation 
    1 .470
**
 .313
**
 .520
**
 .456
**
 .157 -.143 .003 
Sig. (2-
tailed) 
      .000 .001 .000 .000 .112 .148 .978 
N       104 104 104 104 104 104 104 
PWd Pearson 
Correlation 
      1 .758
**
 .593
**
 .454
**
 .402
**
 .178 .249
*
 
Sig. (2-
tailed) 
        .000 .000 .000 .000 .071 .011 
N         104 104 104 104 104 104 
RWT Pearson 
Correlation 
        1 .264
**
 .009 .360
**
 .273
**
 .314
**
 
Sig. (2-
tailed) 
          .007 .929 .000 .005 .001 
N           104 104 104 104 104 
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LVMASS Pearson 
Correlation 
          1 -.001 -.023 -.171 -.062 
Sig. (2-
tailed) 
            .992 .816 .082 .532 
N             104 104 104 104 
LVMI Pearson 
Correlation 
            1 .347
**
 .071 .128 
Sig. (2-
tailed) 
              .000 .472 .196 
N               104 104 104 
CHOLESTEROL Pearson 
Correlation 
              1 .547
**
 .640
**
 
Sig. (2-
tailed) 
                .000 .000 
N                 104 104 
TGL Pearson 
Correlation 
                1 .668
**
 
Sig. (2-
tailed) 
                  .000 
N                   104 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
a. Groups = LVH 
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Correlations
a
 in Non LVH Groups 
  Sr.Calcium LV EDD IVS d PWd RWT LVMASS LVMI CHOLESTEROL TGL LDL 
AGE Pearson 
Correlation 
.063 .077 .049 .055 .012 .105 .107 -.028 -.049 -.025 
Sig. (2-tailed) .530 .444 .627 .586 .909 .291 .286 .779 .624 .806 
N 102 102 102 102 102 102 102 102 102 102 
Sr.Calcium Pearson 
Correlation 
1 .009 .118 .135 .103 .070 .071 .064 .140 .152 
Sig. (2-tailed)   .926 .239 .176 .305 .484 .477 .523 .162 .128 
N   102 102 102 102 102 102 102 102 102 
LV EDD Pearson 
Correlation 
  1 .281** .310** -.450** .824** .824** .019 .019 -.061 
Sig. (2-tailed)     .004 .002 .000 .000 .000 .850 .847 .542 
N     102 102 102 102 102 102 102 102 
IVS d Pearson 
Correlation 
    1 .669** .460** .717** .717** .174 .204* .207* 
Sig. (2-tailed)       .000 .000 .000 .000 .080 .040 .037 
N       102 102 102 102 102 102 102 
PWd Pearson 
Correlation 
      1 .670** .707** .706** -.018 -.012 -.046 
Sig. (2-tailed)         .000 .000 .000 .860 .903 .647 
N         102 102 102 102 102 102 
RWT Pearson 
Correlation 
        1 .078 .077 -.005 -.004 .033 
Sig. (2-tailed)           .437 .441 .957 .968 .740 
N           102 102 102 102 102 
LVMASS Pearson 
Correlation 
          1 1.000** .055 .059 .024 
Sig. (2-tailed)             .000 .585 .553 .815 
N             102 102 102 102 
LVMI Pearson 
Correlation 
            1 .054 .062 .024 
Sig. (2-tailed)               .589 .539 .807 
N               102 102 102 
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CHOLESTEROL Pearson 
Correlation 
              1 .628** .814** 
Sig. (2-tailed)                 .000 .000 
N                 102 102 
TGL Pearson 
Correlation 
                1 .743** 
Sig. (2-tailed)                   .000 
N                   102 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
a. Groups = Non LVH 
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Discussion 
It is now clear that impaired calcium hemostasis is the key factor for cardiac 
hypertrophy, arrhyhthmias and heart failure. Other than direct calcium, dysfunction of 
calcium channels, proteins are also played a role in development of cardiac failure. 
Hypercalcemia causes hypertrophy  in many ways. The most important mechanism is 
calcium calmodulin dependant calcineurin activation that leads translocation of NFAT 
protein into the nucleus. In myocardial cells mitochondria also regulates the calcium 
levels in dyadic space. The calcium overload condition leads to increased myocardial 
calcium uptake that leads to increased oxidative followed by mitochondrial 
dysfunction and death. Myocardial calcifications because of hypercalcemia impairs 
the ventricular relaxation and causes diastolic dysfunction. In our study calcium has 
high positive predictive value for the development of cardiac muscle hypertrophy. 
Increased serum calcium >10.2 is the margin for the development of cardiac 
hypertrophy. Calcium exerts its hypertrophic response through dyslipidemic effect by 
inhibiting cholesterol  catabolism. But statistical analysis shows there is no direct 
correlation between LVH occurance and dyslipidemia. So it is cleared that LVH in 
diabetic patient is due to increased calcium levels. Increased calcium level has a 
positive correlation with LVH occurance. In our study wechecked the albumin 
adjusted serum calcium levels but we have excluded the conditions which causes 
hypoalbuminemia. This study only considered only 1 simple tests for LVH prediction. 
That is serum calcium which is highly  cost effective.  By our study results the main 
influencing factors for left ventricular hypertrophy is left ventricular end diastolic 
dimension, posterior wall thickness and inter ventricular septal thickness. But the 
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increased calcium leads to thickness of all the walls. Hence produces left ventricular 
hypertrophy. Relative wall thickness classifies the type of hypertrophy whether  it is 
concentric or eccentric. Along with this age is also a influencing the left ventricular 
hypertrophy. Initial detection is serum calcium can helpful to identify the risk of 
arrhythmias.  
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CONCLUSION  
 Calcium is the important ion for cardiac and skeletal muscle contraction, 
maintain the blood coagulation and bone mineralization. 
 Increased serum calcium will produce insulin resistance and vise versa. 
 Serum calcium also increases the diabetic prevalence by interacting with 
GLUT 4 receptors.  
 Normal calcium mandatory for excitation contraction coupling but high 
calcium adversely affects the ECC and produces ventricular dysfunction and 
through neurohormonal mechanism it produces cardiac muscle hypertrophy. 
 According to this study increased serum calcium in diabetes has strong 
correlation with occurance of cardiac remodeling. 
 Hence always check the serum calcium level in diabetic patient which will 
predict the development of LVH. 
 Unnecessary calcium supplementation in diabetic patients WILL produces 
many adverse effects including  left ventricle remodeling. 
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MASTER CHART 
GROUP 1 LVH 
AGE LVSD(cm) LVDD(cm) IVS(cm) LVMASS Sr.Calc TGL cholestrol LDL 
45/f 4.4 5.9 1.4 377.6 10.38 197 204 143 
49/M 4.1 5.8 1.4 367.47 10.47 189 211 145 
68/F 5.1 6.1 1.5 398.29 10.56 190 231 152 
56/M 4.8 6 1.5 407.42 10.41 192 231 154 
62/M 5.1 6.1 1.5 398.29 10.43 201 211 154 
68/M 4.9 5.9 1.5 377.6 10.45 209 231 156 
45/M 4.1 6.1 1.4 378.74 10.46 212 223 156 
54/M 4.2 6.1 1.5 398.29 10.76 213 224 156 
56/F 4.9 6.1 1.5 398.29 10.78 198 221 156 
55/m 4.2 6.1 1.5 398.29 10.83 190 212 157 
61/f 4.8 6 1.5 407.42 10.89 197 218 144 
56/f 4.3 5.9 1.5 377.6 10.87 196 219 156 
53/m 4.3 6 1.5 407.42 10.85 189 210 168 
65/m 4.9 6.1 1.5 398.29 10.81 190 231 167 
69/f 4.9 6.1 1.5 398.29 10.78 196 234 165 
49/f 4.5 6.1 1.4 378.74 10.76 190 213 162 
51/m 4.9 5.8 1.4 367.47 10.52 192 219 173 
53/f 4.9 6.1 1.4 378.74 10.64 193 224 169 
57/m 4.9 6 1.5 407.42 10.63 208 229 171 
57/f 4.8 6.1 1.5 398.29 10.73 201 228 176 
68/m 4.9 6.1 1.5 398.29 10.71 203 227 159 
46/m 4.7 5.9 1.4 377.6 10.68 198 229 171 
49/f 4.1 5.8 1.4 367.47 10.61 187 220 154 
49/f 4.4 5.9 1.4 377.6 10.38 197 204 143 
53/m 4.1 5.8 1.4 367.47 10.47 189 211 145 
57/f 5.1 6.1 1.5 398.29 10.56 190 231 152 
51/f 4.8 6 1.5 407.42 10.41 192 231 154 
49/f 5.1 6.1 1.5 398.29 10.43 201 211 154 
48/m 4.9 5.9 1.5 377.6 10.45 209 231 156 
46/m 4.1 6.1 1.4 378.74 10.46 212 223 156 
49/m 4.2 6.1 1.5 398.29 10.76 213 224 156 
49/f 4.9 6.1 1.5 398.29 10.78 198 221 156 
53/m 4.2 6.1 1.5 398.29 10.83 190 212 157 
58/m 4.8 6 1.5 407.42 10.89 197 218 144 
51/f 4.3 5.9 1.5 377.6 10.87 196 219 156 
43/f 4.3 6 1.5 407.42 10.85 189 210 168 
59/m 4.9 6.1 1.5 398.29 10.81 190 231 167 
56/f 4.9 6.1 1.5 398.29 10.78 196 234 165 
45/m 4.5 6.1 1.4 378.74 10.76 190 213 162 
49/f 4.9 5.8 1.4 367.47 10.52 192 219 173 
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47/m 4.9 6.1 1.4 378.74 10.64 193 224 169 
54/m 4.9 6 1.5 407.42 10.63 208 229 171 
49/f 4.8 6.1 1.5 398.29 10.73 201 228 176 
55/m 4.9 6.1 1.5 398.29 10.71 203 227 159 
49/f 4.7 5.9 1.4 377.6 10.68 198 229 171 
51/m 4.1 5.8 1.4 367.47 10.61 187 220 154 
49/f 4.5 6.1 1.4 378.74 10.76 190 213 162 
53/m 4.9 5.8 1.4 367.47 10.52 192 219 173 
51/f 4.9 6.1 1.4 378.74 10.64 193 224 169 
52/f 4.9 6 1.5 407.42 10.63 208 229 171 
49/f 4.8 6.1 1.5 398.29 10.73 201 228 176 
56/m 4.9 6.1 1.5 398.29 10.71 203 227 159 
48/m 4.7 5.9 1.4 377.6 10.68 198 229 171 
49/m 4.1 5.8 1.4 367.47 10.61 187 220 154 
49/f 4.4 5.9 1.4 377.6 10.38 197 204 143 
43/m 4.1 5.8 1.4 367.47 10.47 189 211 145 
49/f 5.1 6.1 1.5 398.29 10.56 190 231 152 
42/m 4.8 6 1.5 407.42 10.41 192 231 154 
41/m 5.1 6.1 1.5 398.29 10.43 201 211 154 
49/f 4.9 5.9 1.5 377.6 10.45 209 231 156 
53/m 4.1 6.1 1.4 378.74 10.46 212 223 156 
56/m 4.2 6.1 1.5 398.29 10.76 213 224 156 
49/f 4.9 6.1 1.5 398.29 10.78 198 221 156 
44/m 4.2 6.1 1.5 398.29 10.83 190 212 157 
45/f 4.8 6 1.5 407.42 10.89 197 218 144 
51/m 4.3 5.9 1.5 377.6 10.87 196 219 156 
50/f 4.3 6 1.5 407.42 10.85 189 210 168 
49/f 4.9 6.1 1.5 398.29 10.81 190 231 167 
43/f 4.9 6.1 1.5 398.29 10.78 196 234 165 
49/f 4.5 6.1 1.4 378.74 10.76 190 213 162 
59/m 4.7 5.9 1.4 377.6 10.68 198 229 171 
48/m 4.1 5.8 1.4 367.47 10.61 187 220 154 
48/m 4.5 6.1 1.4 378.74 10.76 190 213 162 
56/f 4.9 5.8 1.4 367.47 10.52 192 219 173 
59/m 4.9 6.1 1.4 378.74 10.64 193 224 169 
62/f 4.9 6 1.5 407.42 10.63 208 229 171 
49/f 4.8 6.1 1.5 398.29 10.73 201 228 176 
50/f 4.9 6.1 1.5 398.29 10.71 203 227 159 
49/f 4.7 5.9 1.4 377.6 10.68 198 229 171 
54/f 4.1 5.8 1.4 367.47 10.61 187 220 154 
56/m 4.4 5.9 1.4 377.6 10.38 197 204 143 
49/f 4.1 5.8 1.4 367.47 10.47 189 211 145 
48/m 5.1 6.1 1.5 398.29 10.56 190 231 152 
45/f 4.8 6 1.5 407.42 10.41 192 231 154 
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49/f 5.1 6.1 1.5 398.29 10.43 201 211 154 
43/m 4.9 5.9 1.5 377.6 10.45 209 231 156 
40/f 4.1 6.1 1.4 378.74 10.46 212 223 156 
59/m 4.2 6.1 1.5 398.29 10.76 213 224 156 
63/f 4.2 6.1 1.5 398.29 10.83 190 212 157 
62/m 4.8 6 1.5 407.42 10.89 197 218 144 
40/m 4.3 5.9 1.5 377.6 10.87 196 219 156 
56/m 4.3 6 1.5 407.42 10.85 189 210 168 
59/m 4.9 6.1 1.5 398.29 10.81 190 231 167 
65/f 4.9 6.1 1.5 398.29 10.78 196 234 165 
 
Group 2 NON LVH 
AGE LVSD LVDD IVS LVMASS Sr.Calc TGL cholestrol LDL 
52/m 2.5 4.3 1 155.8 8.91 109 156 74 
50/m 2.8 4.3 0.9 157.39 8.9 111 154 78 
49/m 2.8 4.4 1 165.57 9.21 132 176 82 
53/m 2.6 4.4 1 165.57 9.13 114 178 87 
51/f 2.5 4.5 0.9 156.83 9.17 132 167 90 
52/m 2.6 4.3 1 155.8 9.02 131 154 73 
51/f 2.6 4.5 0.9 156.82 9.03 109 159 87 
51/m 2.5 4.4 1 165.57 9.12 114 169 79 
51/m 2.8 4.4 0.9 118.58 9.21 119 160 83 
49/m 2.6 4.3 0.9 157.39 9.03 117 151 93 
53/m 2.6 4.3 1 155.8 8.98 116 159 89 
54/f 2.8 4.4 1 165.57 8.93 116 162 92 
51/m 2.6 4.3 1 155.8 8.9 119 153 71 
51/m 2.6 4.3 0.9 114.17 9.12 110 159 98 
52/f 2.7 4.3 0.9 157.39 9.14 121 163 87 
54/m 2.5 4.3 1 138.31 9.03 132 163 92 
51/f 2.7 4.3 1 155.8 8.96 34 172 76 
49/m 2.5 4.3 1 155.8 8.98 121 167 79 
51/m 2.6 4.4 1 165.57 9.08 107 162 83 
49/m 2.6 4.5 1 142.28 9.05 121 153 92 
52/f 2.6 4.3 1 155.8 9.05 119 172 82 
53/f 2.6 4.5 0.9 156.82 8.95 139 168 88 
51/m 2.8 4.3 0.9 157.39 9.08 126 170 92 
50/f 2.8 4.4 0.9 118.58 9.21 119 160 83 
49/f 2.6 4.3 0.9 157.39 9.03 117 151 93 
54/f 2.6 4.3 1 155.8 8.98 116 159 89 
56/m 2.8 4.4 1 165.57 8.93 116 162 92 
49/f 2.6 4.3 1 155.8 8.9 119 153 71 
48/m 2.6 4.3 0.9 114.17 9.12 110 159 98 
45/f 2.7 4.3 0.9 157.39 9.14 121 163 87 
49/f 2.5 4.3 1 138.31 9.03 132 163 92 
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43/m 2.7 4.3 1 155.8 8.96 34 172 76 
40/f 2.5 4.3 1 155.8 8.98 121 167 79 
59/m 2.6 4.4 1 165.57 9.08 107 162 83 
63/f 2.6 4.5 1 142.28 9.05 121 153 92 
62/m 2.6 4.3 1 155.8 9.05 119 172 82 
40/m 2.6 4.5 0.9 156.82 8.95 139 168 88 
56/m 2.8 4.3 0.9 157.39 9.08 126 170 92 
59/m 2.5 4.3 1 155.8 8.91 109 156 74 
65/f 2.8 4.3 0.9 157.39 8.9 111 154 78 
53/m 2.8 4.4 1 165.57 9.21 132 176 82 
56/m 2.6 4.4 1 165.57 9.13 114 178 87 
49/f 2.5 4.5 0.9 156.83 9.17 132 167 90 
44/m 2.6 4.3 1 155.8 9.02 131 154 73 
45/f 2.6 4.5 0.9 156.82 9.03 109 159 87 
51/m 2.5 4.4 1 165.57 9.12 114 169 79 
50/f 2.7 4.3 0.9 157.39 9.14 121 163 87 
49/f 2.5 4.3 1 138.31 9.03 132 163 92 
43/f 2.7 4.3 1 155.8 8.96 34 172 76 
49/f 2.5 4.3 1 155.8 8.98 121 167 79 
59/m 2.6 4.4 1 165.57 9.08 107 162 83 
48/m 2.6 4.5 1 142.28 9.05 121 153 92 
48/m 2.6 4.3 1 155.8 9.05 119 172 82 
56/f 2.6 4.5 0.9 156.82 8.95 139 168 88 
59/m 2.8 4.3 0.9 157.39 9.08 126 170 92 
62/f 2.5 4.3 1 155.8 8.91 109 156 74 
49/f 2.8 4.3 0.9 157.39 8.9 111 154 78 
58/m 2.8 4.4 1 165.57 9.21 132 176 82 
51/f 2.6 4.4 1 165.57 9.13 114 178 87 
43/f 2.6 4.3 1 155.8 8.9 119 153 71 
59/m 2.6 4.3 0.9 114.17 9.12 110 159 98 
56/f 2.7 4.3 0.9 157.39 9.14 121 163 87 
45/m 2.5 4.3 1 138.31 9.03 132 163 92 
49/f 2.7 4.3 1 155.8 8.96 34 172 76 
47/m 2.5 4.3 1 155.8 8.98 121 167 79 
54/m 2.6 4.4 1 165.57 9.08 107 162 83 
49/f 2.6 4.5 1 142.28 9.05 121 153 92 
55/m 2.6 4.3 1 155.8 9.05 119 172 82 
49/f 2.6 4.5 0.9 156.82 8.95 139 168 88 
51/m 2.8 4.3 0.9 157.39 9.08 126 170 92 
49/f 2.8 4.4 0.9 118.58 9.21 119 160 83 
53/m 2.6 4.3 0.9 157.39 9.03 117 151 93 
51/f 2.6 4.3 1 155.8 9.02 131 154 73 
52/f 2.6 4.5 0.9 156.82 9.03 109 159 87 
49/f 2.5 4.4 1 165.57 9.12 114 169 79 
89 
 
56/m 2.8 4.4 0.9 118.58 9.21 119 160 83 
45/f 2.6 4.3 0.9 157.39 9.03 117 151 93 
49/M 2.6 4.3 1 155.8 8.98 116 159 89 
68/F 2.8 4.4 1 165.57 8.93 116 162 92 
56/M 2.6 4.3 1 155.8 8.9 119 153 71 
62/M 2.6 4.3 0.9 114.17 9.12 110 159 98 
68/M 2.7 4.3 0.9 157.39 9.14 121 163 87 
45/M 2.5 4.3 1 138.31 9.03 132 163 92 
54/M 2.7 4.3 1 155.8 8.96 34 172 76 
56/F 2.5 4.3 1 155.8 8.98 121 167 79 
55/m 2.6 4.4 1 165.57 9.08 107 162 83 
61/f 2.8 4.3 0.9 157.39 8.9 111 154 78 
56/f 2.8 4.4 1 165.57 9.21 132 176 82 
53/m 2.6 4.4 1 165.57 9.13 114 178 87 
65/m 2.5 4.5 0.9 156.83 9.17 132 167 90 
69/f 2.6 4.3 1 155.8 9.02 131 154 73 
49/f 2.6 4.5 0.9 156.82 9.03 109 159 87 
51/m 2.5 4.4 1 165.57 9.12 114 169 79 
53/f 2.7 4.3 0.9 157.39 9.14 121 163 87 
57/m 2.5 4.3 1 138.31 9.03 132 163 92 
57/f 2.7 4.3 1 155.8 8.96 34 172 76 
45/M 2.5 4.3 1 155.8 8.98 121 167 79 
54/M 2.6 4.4 1 165.57 9.08 107 162 83 
56/F 2.6 4.5 1 142.28 9.05 121 153 92 
61/f 2.6 4.3 1 155.8 9.05 119 172 82 
56/f 2.6 4.5 0.9 156.82 8.95 139 168 88 
53/m 2.8 4.3 0.9 157.39 9.08 126 170 92 
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PROFORMA 
 Name:                                                     Age/sex:                                             
 Address:                                                IPNO/OP NO: 
 DM – Yes/No                                       HT- Yes/ No 
 Diagnosis: 
 BMI: 
QUESTIONNAIRE:  
 Kuppusamy Socio economic State: 
 Family History of DM / hypertension 
 Do you exercise regularly : 
 Diet restriction :  
 H/o hypothyroidism/ hyperparathyroidism 
 H/O previous cardiac illness : 
 h/o any mediaction in past and current: 
 h/o alcoholism / smoking  
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சுயஒப்புதல்படிவம் 
 ஆய்வுசெய்யப்படும்தலைப்பு:நீரிழிவுநநோயில்அதிககோல்ெியத்தோல்இருதய
த்தில்ஏற்படும்போதிப்புகள்பற்றியஆய்வு.  
 இடம்:சபோதுமருத்துவத்துவதுலை    
அைசுகீழ்போக்கம்மருத்துவகல்லூரிமருத்துவமலை  சென்லை  
 பங்குசபறுபவரின்சபயர் :  
 பங்குசபறுபவரின்வயது :                             பங்குசபறுபவரின்எண் : 
                    நமநை  குறிப்பிட்டுள்ள மருத்துவஆய்வின் விவைங்கள்எைக்கு 
விளக்கப்பட்டது. நோை இவ்வோய்வில்   தன்ைிச்லெயோக  பங்நகற்கிநறன். 
எந்தகோைணத்திைோநைோ எந்த ெட்டெிக்கலுக்கும்  
          உட்படோமல் நோன் இவ்வோய்வில் இருந்து விைகிக்சகோள்ளல்ைோம் என்றும் 
அறிந்துசகோண்நடன். 
                     இந்த ஆய்வு ெம்பந்தமோகநவோ,  இலத ெோர்ந்து நமலும் ஆய்வு 
நமற்சகோள்ளும்நபோதும் இந்த ஆய்வில்  பங்குசபறும் மருத்துவர் என்னுலடய 
மருத்துவஅறிக்லககலள போர்ப்பதற்கு என்அனுமதி நதலவயில்லை எை அறிந்து 
சகோள்கிநறன் இந்த ஆய்வின் மூைம் கிலடக்கும் தகவலைநயோ, முடிலவநயோ 
பயன்படுத்திக் சகோள்ள மறுக்கமோட்நடன். 
                     இந்த ஆய்வில் பங்கு சகோள்ள ஒப்புக் சகோள்கிநறன். 
 .                   இந்த ஆய்லவ நமற்சகோள்ளும் மருத்துவ அணிக்கு உண்லமயுடன் 
இருப்நபன் என்றும் உறுதியளிக்கிநறன். 
                                                                                                             பங்நகற்பவரின்லகசயோப்பம்                                                           
ஆய்வோளரின்லகசயோப்பம்  
 இடம் : 
 நததி : 
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